Latest News

Written by Ι Stock Market Media — December 3, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is steadily growing its footprint in the high-tech space while also expanding its already strong portfolio of technologies that continue to increase the company’s position in the industry.  GBT is segmented into 5 different areas of growth, but its work in the artificial intelligence or AI industry continues to be the company’s central focus, and its AI engine, “Avant! AI,” could prove to be an industry-leading ...

Written by Ι Stock Market Media — November 12, 2019

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA.  PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).  With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

PharmaCyte has already ...

Written by Ι Stock Market Media — November 8, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) has a vast portfolio of intellectual property that spans both the Artificial Intelligence (AI) and Internet of Things (IoT) markets.  But the company’s central focus is on a technology called “Avant! AI”—a technology that could become commonplace in both businesses and households worldwide.  It is the extremely promising potential of Avant! that has GBT Technologies (GBT) ideally positioned to compete in what Gartner, a leading research and ...

Written by Ι Stock Market Media — October 28, 2019

PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future.  The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically.  It is an outcome that would ...

Written by Ι Stock Market Media — October 16, 2019

NEW YORK, NY, Oct. 16, 2019 — PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to request a clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) in the United States.  The company has successfully completed the first of two manufacturing runs to produce the clinical trial product (Cell-in-a-Box^® capsules) it needs for ...

Written by Ι Stock Market Media — August 26, 2019

New York, NY — Tech Central, Inc. (OTC Markets: TCHC) entered the CBD market this year (2019) with an aggressive approach that not only included launching its own CBD products, but also includes helping burgeoning businesses build their exclusive CBD brand in the industry as well.

In just a few short months, the company has announced the development of its “CBD Affiliate Marketer” app, launched its “Better Mind CBD” line ...